Cargando…

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516221/ http://dx.doi.org/10.1007/s40278-020-83929-5

Ejemplares similares

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Exanthema and eosinophilia: 12 case reports
Publicado: (2020)

Immunosuppressants/lopinavir/ritonavir interaction: Various toxicities: case report
Publicado: (2020)

Dexamethasone/hydroxychloroquine/lopinavir/ritonavir: Various toxicities: case report
Publicado: (2021)

Lopinavir/ritonavir/sotalol: Various toxicities: 9 case reports
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Various side effects: 7 case reports
Publicado: (2020)

Lopinavir/ritonavir: Hyperlipidaemia following off-label use: case report
Publicado: (2020)

Lopinavir/ritonavir: Bradyarrhythmia following an off-label use : case report
Publicado: (2020)

Lopinavir/ritonavir/prednisone: Knee osteonecrosis and its worsening: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Bradycardia and off-label-use: case report
Publicado: (2021)

Lopinavir/ritonavir: Diarrhoea following off label use: case report
Publicado: (2021)

Lopinavir/ritonavir: Maculopapular rash following off-label use: case report
Publicado: (2020)

Baricitinib/lopinavir/ritonavir: Elevated transaminases and off-label use: case report
Publicado: (2020)

Lopinavir/ritonavir: Acute liver failure following compassionate use: case report
Publicado: (2020)

Lopinavir/ritonavir: Cardiotoxicities following off-label use: 4 case reports
Publicado: (2021)

Lopinavir/ritonavir: Nausea and vomiting following off label use: case report
Publicado: (2021)

Lopinavir/ritonavir: Hepatic cytolysis following off-label use: case report
Publicado: (2021)

Lopinavir/ritonavir: Lichen planus following off-label use: case report
Publicado: (2021)

Lopinavir/ritonavir/tocilizumab: Hypertriglyceridaemia following off-label use: 2 case reports
Publicado: (2020)

Lopinavir/ritonavir/ribavirin: Various toxicities following off-label treatment: case report
Publicado: (2020)

Lopinavir/ritonavir: Sick sinus syndrome following off-label use: case report
Publicado: (2020)

Lopinavir/ritonavir: Hepatobiliary disorder and hypertriglyceridaemia following off label use: case report
Publicado: (2021)

Ceftriaxone/levofloxacin/lopinavir/ritonavir: Thrombocytopenia following off-label use: case report
Publicado: (2021)

Lopinavir/ritonavir: Lack of efficacy following off-label use: 2 case reports
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir: Guillain-Barre-syndrome and off-label-use: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy and off label use: 3 case reports
Publicado: (2022)

Lopinavir/ritonavir/sirolimus interaction: Hepatitis following an off-label use: case report
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy following off-label use: case report
Publicado: (2022)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

COVID-19 treatment with lopinavir–ritonavir resulting in sick sinus syndrome: a case report
por: Wang, Laureen Yi-Ting, et al.
Publicado: (2020)

Lopinavir/ritonavir: Third-degree atrioventricular block following off-label use: case report
Publicado: (2020)

Lopinavir/ritonavir: Worsening of liver injury following off-label use: 7 case reports
Publicado: (2020)

Lopinavir/ritonavir: Acute kidney injury following off-label use: 8 case reports
Publicado: (2020)

Lopinavir/ritonavir/rocuronium bromide interaction: Myopathy following off-label use: case report
Publicado: (2021)

Azithromycin/lopinavir/ritonavir: Acute kidney injury following off label use: case report
Publicado: (2021)

Ciclesonide/favipiravir/lopinavir/ritonavir: Off-label use, pancytopenia and liver dysfunction: case report
Publicado: (2021)

Lopinavir/ritonavir/umifenovir: Nausea, vomiting and diarrhoea following off-label treatment: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir/tocilizumab: Lack of efficacy following off label use: case report
Publicado: (2022)

Lopinavir/ritonavir: Acute hepatocellular hepatitis following off-label use in COVID-19: case report
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Acute generalised exanthematous pustulosis with erythema multiforme-like lesions: case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9t18fsefjd58juuvnid025p8r7